HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Divine Skin enters Brazil

This article was originally published in The Rose Sheet

Executive Summary

Miami Beach-based biotech firm launches its first Latin American subsidiary - DS Laboratories do Brasil Ltd. - complete with local office, resident pharmacist and sales force in place. "This is a major milestone in the meteoric growth of Divine Skin worldwide," says Daniel Khesin, founder and chief executive, adding: "We expect Brazilian sales to be visible in 2010 figures and to contribute strongly in 2011 and beyond." Firm's flagship DS Laboratories brand expects its Nia radiant color shampoo and conditioner and Nirena pH-balanced feminine cleanser to roll out first in Brazil, as they are considered Level-1 cosmetics of minimal risk, Divine Skin indicates in its Oct. 4 release. The company's Oligo.DX cellulite-reducing gel is concluding 60-day efficiency testing, required of Level-2 cosmetics in Brazil, and has demonstrated an "astounding" 90% success rate, according to the firm. Efficiency tests for Divine Skin's Revita hair-growth-stimulating shampoo should wrap by the end of October, and tests for the rest of the DS Laboratories line should be finished by the year's end, Divine Skin notes. Firm cites Brazil's gross domestic product of $2 tril. and population growth rate of 1.2% annually. Divine Skin launched a dedicated consumer health division in July (1"The Rose Sheet" July 12, 2010)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel